

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome/Cognome

SERGIO ABRIGNANI

UNIVERSITÀ DEGLI STUDI DI MILANO - UNIMI

INGM ISTITUTO NAZIONALE GENETICA MOLECOLARE "ROMEO ED ENRICA INVERNIZZI"

PADIGLIONE INVERNIZZI - VIA FRANCESCO SFORZA, 35 – 20122 MILANO

Indirizzo

Telefono Ufficio

02 0066 0328

E-mail

[REDACTED]

CODICE FISCALE

[REDACTED]

Nazionalità

Italiana

Data di nascita

[REDACTED]

Luogo di nascita

[REDACTED]

ORCID ID

0000-0002-0794-3285

ESPERIENZA LAVORATIVA

- Date (da - a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

01 Giugno 2015

Università degli Studi di Milano – Via Festa del Perdono, 7 – 20122 Milano

Università

Professore ordinario di Patologia Generale - Dipartimento di Scienze Cliniche e di Comunità (DISCCO)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

01 Gennaio 2006

FONDAZIONE INGM Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi"

Centro di Ricerca Biomedica finalizzato alla scoperta e allo sviluppo iniziale di nuovi mezzi diagnostici, nuove terapie e vaccini.

Direttore Scientifico

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

1999-2005

Chiron Corporation, Emeryville (CA), USA

Biotecnologia

Vice Presidente, Dipartimento di ricerca e sviluppo

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

1994 – 2000

Università di Siena

Scuola di specializzazione in Gastroenterologia, Facoltà di Medicina

Professore a contratto

- Date (da – a)
- Nome e indirizzo del datore di lavoro
- Tipo di azienda o settore
- Tipo di impiego

Aprile 1993 – 1999

Centro Ricerche Chiron - Siena

Biotecnologia

Direttore del Dipartimento di Immunologia e Virologia

- Date (da – a) 1990 – Marzo 1992
- Nome e indirizzo del datore di lavoro Ciba-Geigy, Basilea, Svizzera
- Tipo di azienda o settore
- Tipo di impiego Responsabile del Laboratorio Vaccini presso il Dipartimento di Allergia/Immunologia

- Date (da – a) 1988 – 1989
- Nome e indirizzo del datore di lavoro Ciba-Geigy, Basilea, Svizzera
- Tipo di azienda o settore
- Tipo di impiego Ricercatore presso il Dipartimento di Allergia/Immunologia

- Date (da – a) 1986 – 1987
- Nome e indirizzo del datore di lavoro Sandoz, Basilea, Svizzera
- Tipo di azienda o settore
- Tipo di impiego Ricercatore presso il Dipartimento di Ricerca Preclinica

- Date (da – a) 1983 – 1985
- Nome e indirizzo del datore di lavoro Istituto di Patologia Generale, Facoltà di Medicina, Università di Palermo
- Tipo di azienda o settore
- Tipo di impiego Assistente Medico

PREMI E RICONOSCIMENTI

- Date (da-a)

2011-2016

ERC Advanced Grant

"Lymphocyte microRNAs in health and disease: Understanding lymphocyte functions through the identification of microRNA target genes and exploiting serum microRNA signatures to monitor immune responses".

- Date (da-a)

2004

Medaglia d'oro al merito della Salute Pubblica, per i suoi studi sul virus dell'epatite C

ISTRUZIONE E FORMAZIONE

- Date (da - a)

- Nome e tipo di istituto di istruzione o formazione

1986

Facoltà di Medicina dell'Università di Palermo

- Qualifica conseguita

Specializzazione in Patologia Generale, votazione 70/70 con lode

- Date (da - a)

- Nome e tipo di istituto di istruzione o formazione

1982

Facoltà di Medicina dell'Università di Padova

- Qualifica conseguita

Abilitazione nazionale all'esercizio della professione medica

- Date (da - a)

- Nome e tipo di istituto di istruzione o formazione

1982

Facoltà di Medicina dell'Università di Padova

- Qualifica conseguita

Laurea in medicina, votazione 110/110 con lode

PRIMA LINGUA
ALTRE LINGUE
Autovalutazione
Livello europeo ()*

ITALIANO

Comprensione

Parlato

Scritto

Ascolto

Lettura

Interazione

Produzione orale

Inglese

C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato C2 Utente avanzato

Tedesco

B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo B1 Utente autonomo

(*) Quadro comune europeo di riferimento per le lingue

**ALTRE ATTIVITÀ
PROFESSIONALI**

Board of Directors: not for profit institutions:

2006 –	Fondazione INGM, Milano	Membro del Consiglio di Amministrazione
2015 –	Sclavo Vaccines Association, Siena	Membro del Consiglio di Amministrazione
2017 –	Fondazione Carlo Erba, Milano	Membro del Consiglio di Amministrazione
2021 -	Fondazione Toscana Life Sciences, Siena	Membro del Consiglio di Indirizzo
2022 -	Fondazione Enea Tech e Biomedical, Roma	Membro del Consiglio Direttivo

Board of Directors: Companies:

2015 –	Impact Lab Srl, Milano	Membro del Consiglio di Amministrazione
2018 –	CheckmAb Srl, Milano	Membro del Consiglio di Amministrazione
2021 -	Utopia SIS Spa, Bologna	Membro del Consiglio di Amministrazione

Advisory Board membership:

2013 -	IRCCS Ospedale Policlinico, Milano	Membro del Comitato Etico
2018 -	Ministero della Salute	Membro del Comitato Tecnico Sanitario
2019 -	Ministero della Salute	Membro del Consiglio Superiore di Sanità
2021 – 2022	Presidenza del Consiglio dei Ministri	Membro del CTS Emergenza Covid19
2021 -	Regione Lombardia	Membro del gruppo tecnico nella campagna vaccinale anti Covid19

“ad hoc reviewer” di articoli sulle seguenti riviste scientifiche:

European Journal of Immunology, EMBO Journal, Frontiers in Immunology, Hepatology, Immunity, International Immunology, Journal of Clinical Investigation, Journal of Hepatology, Journal of Immunology, Nature, Nature Immunology, Nature Medicine, Science.

Publicazioni

H index, secondo Google Scholar: **73**

Totale citazioni, secondo Google Scholar: **21491**

() indica che Sergio Abrignani è corresponding author**

2022

1. Borghi MO, Bombaci M, Bodio C, Lonati PA, Gobbini A, Lorenzo M, Torresani E, Dubini A, Bulgarelli I, Solari F, Pregnotato F, Bandera A, Gori A, Parati G, **Abrignani S**, Grifantini R, Meroni PL. "Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers". Front Immunol. 2022 Jul 15;13:930074.
2. Moschetti G, Vasco C, Clemente F, Galeota E, Carbonara M, Pluderi M, Locatelli M, Stocchetti N, **Abrignani S**, Zanier ER, Ortolano F, Zoerle T, Geginat J. "Deep Phenotyping of T-Cells Derived From the Aneurysm Wall in a Pediatric Case of Subarachnoid Hemorrhage". Front Immunol. 2022 May 31;13:866558.
3. Favalli A, Favalli EG, Gobbini A, Zagato E, Bombaci M, Maioli G, Pesce E, Donnici L, Guarin P, Biggioggero M, Curti S, Manganaro L, Marchisio E, Bevilacqua V, Martinovic M, Fabbris T, Sarnicola ML, Crosti MC, Marongiu L, Granucci F, Notarbartolo S, Bandera A, Gori A, De Francesco R, **Abrignani S**, Caporali R, Grifantini R. "Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Population". Front Immunol. 2022 Jun 10;13:873195.

4. Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandiera A, Gori A, **Abri gnani S**, Grifantini R, Caporali R. "The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study". *Front Med (Lausanne)*. 2022 Mar 11;9:850858.
5. Lenti E, Genovese L, Bianchessi S, Maurizio A, Sain SB, di Lillo A, Mattavelli G, Harel I, Bernassola F, Hehl gans T, Pfeffer K, Crosti M, **Abri gnani S**, Evans SM, Sitia G, Guimarães-Camboa N, Russo V, van de Pavert SA, Garcia-Manteiga JM, Brendolan A. "Fate mapping and scRNA sequencing reveal origin and diversity of lymph node stromal precursors". *Immunity*. 2022 Apr 12;55(4):606-622.e6.
6. (**) Marasca F, Sinha S, Vadalà R, Polimeni B, Ranzani V, Paraboschi E, Burattin FV, Ghilotti M, Crosti MC, Negri ML, Campagnoli S, Notarbartolo S, Bianchi AS, Siena S, Prati D, Montini G, Viale G, Torre O, Harari S, Grifantini R, Soldà G, Biffo S, **Abri gnani S**, Bodega B. "LINE1 elements are spliced in non-canonical transcript variants to control gene expression in human T cell quiescence and exhaustion". *Nat Genet*. 2022 Feb;54(2):180-193.
7. Pesce E, Manfrini N, Cordiglieri C, Santi S, Bandera A, Gobbini A, Gruarin P, Favalli A, Bombaci M, Cuomo A, Collino F, Cricri G, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, Gori A, **Abri gnani S**, De Francesco R, Biffo S, Grifantini R. "Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response". *Front Immunol*. 2022 Jan 17;12:785941.
8. Elia D, Torre O, Vasco C, Geginat J, **Abri gnani S**, Bulgheroni E, Carelli E, Cassandro R, Pacheco-Rodriguez G, Steagall WK, Moss J, Harari S. "Pulmonary Langerhans cell histiocytosis (PLCH) and lymphangioleiomyomatosis (LAM) have circulating cells with loss of heterozygosity of the TSC2 gene". *Chest*. 2022 Feb 26:S0012-3692(22)00398-1.
9. Lonati PA, Bodio C, Scavone M, Martini G, Pesce E, Bandera A, Lombardi A, Gerosa M, Franceschini F, Tincani A, Podda G, **Abri gnani S**, Grifantini R, Cattaneo M, Borghi MO, Meroni PL. "Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination". *RMD Open*. 2022 Feb;8(1):e001902.

10. Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D, Grifantini R, **Abrignani S**, Siena S, Scaglione F, Sartore-Bianchi A. "Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment". *Eur J Cancer*. 2021 Dec 22;163:16-25.
11. Lombardi A, Butta GM, Donnici L, Bozzi G, Oggioni M, Bono P, Matera M, Consonni D, Ludovisi S, Muscatello A, Ceriotti F, Conti M, Scaglioni S, Gallo G, Scarpa E, Letko M, **Abrignani S**, Grifantini R, De Francesco R, Gori A, Manganaro L, Bandera A. "Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study". *Lancet Reg Health Eur*. 2021 Dec 23:100287.
12. Marongiu L, Protti G, Facchini FA, Valache M, Mingozi F, Ranzani V, Putignano AR, Salviati L, Bevilacqua V, Curti S, Crosti M, Sarnicola ML, D'Angiò M, Bettini LR, Biondi A, Nespoli L, Tamini N, Clementi N, Mancini N, **Abrignani S**, Spreafico R, Granucci F. "Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing". *Eur J Immunol*. 2022 Jan;52(1):109-122.

2021

13. De Ponte Conti B, Miluzio A, Grassi F, **Abrignani S**, Biffo S, Ricciardi S. "mTOR-dependent translation drives tumor infiltrating CD8+ effector and CD4+ Treg cells expansion". *Elife*. 2021 Nov 17;10:e69015.
14. Cossarizza A, Chang HD, Radbruch A, **Abrignani S**, *et al.* "Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)". *Eur J Immunol*. 2021 Dec;51(12):2708-3145.
15. De Simone M, Chirichella M, Emming S, Mazzara S, Ranzani V, Gruarin P, Moschetti G, Pulvirenti N, Maglie S, Vasco C, Crosti MC, Rossetti G, Pagani M, **Abrignani S**, Monticelli S, Geginat J. "Ex vivo microRNA and gene expression profiling of human Tr1-like cells suggests a role for miR-92a and -125a in the regulation of EOMES and IL-10R". *Eur J Immunol*. 2021 Dec;51(12):3243-3246.
16. (**) Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, Gobbini A, Galeota E, Manara C, Bombaci M, Pesce E, Zagato E, Favalli A, Sarnicola

ML, Curti S, Crosti M, Martinovic M, Fabbris T, Marini F, Donnici L, Lorenzo M, Mancino M, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, De Feo T, Prati D, Manganaro L, Granucci F, Lanzavecchia A, De Francesco R, Gori A, Grifantini R, **Abrignani S**. "Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients". *Sci Immunol*. 2021 Aug 10;6(62):eabg5021.

17. Poli A, Abdul-Hamid S, Zaurito AE, Campagnoli F, Bevilacqua V, Sheth B, Fiume R, Pagani M, **Abrignani S**, Divecha N. "PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity". *Proc Natl Acad Sci U S A*. 2021 Aug 3;118(31):e2010053118.
18. (**) Bonnal RJP, Rossetti G, Lugli E, De Simone M, Gruarin P, Brummelman J, Drufuca L, Passaro M, Bason R, Gervasoni F, Della Chiara G, D'Oria C, Martinovic M, Curti S, Ranzani V, Cordiglieri C, Alvisi G, Mazza E, Oliveto S, Silvestri Y, Carelli E, Mazzara S, Bosotti R, Sarnicola ML, Godano C, Bevilacqua V, Lorenzo M, Siena S, Bonoldi E, Sartore-Bianchi A, Amatu A, Veronesi G, Novellis P, Alloisio M, Giani A, Zucchini N, Opocher E, Pisani Ceretti A, Mariani N, Biffo S, Prati D, Bardelli A, Geginat J, Lanzavecchia A, **Abrignani S**, Pagani M. "Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors associate with disease progression". *Nat Immunol*. 2021 Jun;22(6):735-745.
19. Fontana C, Marasca F, Provitera L, Mancinelli S, Pesenti N, Sinha S, Passera S, **Abrignani S**, Mosca F, Lodato S, Bodega B, Fumagalli M "Early maternal care restores LINE-1 methylation and enhances neurodevelopment in preterm infants" *BMC Med*. 2021 Feb 5;19(1):42.

2020

20. Pammolli F, Righetto L, **Abrignani S**, Pani L, Pelicci PG, Rabosio E. "The endless frontier? The recent increase of R&D productivity in pharmaceuticals". *J Transl Med*. 2020 Apr 9;18(1):162.
21. Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, **Abrignani S**, Fantini MC, Vecchi M, Geginat J, Caprioli F. "Immunological variables associated with clinical and endoscopic response to vedolizumab in patients

with inflammatory bowel diseases." J Crohns Colitis. 2020 Feb 26;jjaa035.

22. Magri A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, **Abrignani S**, D'Incalci M, Zucchetti M, Di Nicolantonio F, Bardelli A. "High-dose vitamin C enhances cancer immunotherapy." Sci Transl Med. 2020 Feb 26;12(532).
23. Facciotti F, Larghi P, Bosotti R, Vasco C, Gagliani N, Cordiglieri C, Mazzara S, Ranzani V, Rottoli E, Curti S, Penatti A, Karnani B, Kobayashi Y, Crosti M, Bombaci M, van Hamburg JP, Rossetti G, Gualtierotti R, Gerosa M, Gatti S, Torretta S, Pignataro L, Tas SW, **Abrignani S**, Pagani M, Grassi F, Meroni PL, Flavell RA, and Geginat J. "Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus". PNAS USA. 2020 Mar 31;117(13):7305-7316.
24. Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella C, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, **Abrignani S**, Siena S, Di Nicolantonio F, Bardelli A. "A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin". Clin Cancer Res. 2020 Mar 15;26(6):1372-1384.

2019

25. Geginat J, Vasco M, Gerosa M, Tas SW, Pagani M, Grassi F, Flavell RA, Meroni P, **Abrignani S**. "IL-10 producing regulatory and helper T-cells in systemic lupus erythematosus". Semin Immunol. 2019 Aug;44:101330.
26. Gruarin P, Maglie S, De Simone M, Häring B, Vasco C, Ranzani V, Bosotti R, Noddings JS, Larghi P, Facciotti F, Sarnicola ML, Martinovic M, Crosti M, Moro M, Rossi RL, Bernardo ME, Caprioli F, Locatelli F, Rossetti G, **Abrignani S**, Pagani M, Geginat J. "Eomesodermin controls a unique differentiation program in human IL-10 and IFN- γ coproducing regulatory T cells". Eur J Immunol. 2019 Jan;49(1):96-111.
27. (**). Bombaci M, Pesce E, Torri A, Carpi A, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano L, Invernizzi P, **Abrignani S**, Grifantini R. "Novel biomarkers for Primary Biliary Cholangitis to

improve diagnosis and understand underlying regulatory mechanisms". *liver Int.* 2019 Nov;39(11):2124-2135.

2018

28. Ricciardi S, Manfrini N, Alfieri R, Calamita P, Crosti MC, Simone G, Müller R, Pagani M, **Abbrignani S**, Biffo S "The Translational Machinery of Human CD4+ T Cells Is Poised for Activation and Controls the Switch from Quiescence to Metabolic Remodeling". *Cell Metab.* 2018 Dec 4;28(6):961.
29. Costanzo V, Bardelli A, Siena S, **Abbrignani S**. "Exploring the links between cancer and placenta development". *Open Biology.* 2018 Jun;8(6):180081.
30. Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Guarini P, Vasco CM, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti MC, Gatti S, Pagani M, Caprioli F, **Abbrignani S**, Flavell RA, Geginat J. "Intestinal IFN- γ -producing Tr1-cells co-express CCR5 and PD-1, and down regulate IL-10 in the inflamed gut of IBD patients". *J Allergy Clin Immunol.* 2018 Nov;142(5):1537-1547.e8.

2017

31. (**) Ripamonti A, Provasi E, Lorenzo M, De Simone M, Ranzani V, Vangelisti S, Curti S, Bonnal RJP, Torretta S, Geginat, Tossetti G, Pagani M, **Abbrignani S**. "Repression of miR-31 by BCL6 stabilizes the helper function of human follicular helper T cells". *PNAS* 2017; 114(48):12797-12802.
32. Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, **Abbrignani S**, Grandi G, Pileri P, Rots MG, Grifantini R. "TCTN2: a novel tumor marker with oncogenic properties". *Oncotarget.* 2017 Aug 24;8(56):95256-95269.
33. Ferlito C, Barnaba V, **Abbrignani S**, Bombaci M, Sette A, Sidney J, Biselli R, Tomao E, Cattaruzza MS, Germano V, Biondo MI, Salerno G, Lulli P, Caporuscio S, Diamanti AP, Falco M, Biselli V, Cardelli P, Autore A, Lucertini E, Pompeo De Cesare DP, Peragallo MS, Lista F, Martire C, Salemi S, Nisini R,

- D'Amelio R. „Lack of evidence for post-vaccine onset of autoimmune/lymphoproliferative disorders, during a nine-month follow-up in multiply vaccinated Italian military personnel“. *Clin Immunol.* 2017 Aug;181:60-66.
34. Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, Scarpini E, **Abrignani S**. „The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?“ *Trends Immunol.* 2017 Jul;38(7):498-512.
35. Penatti A, Facciotti F, De Matteis R, Larghi P, Paroni M, Murgo A, De Lucia O, Pagani M, Pierannunzii L, Truzzi M, Ioan-Facsinay A, **Abrignani S**, Geginat J, Meroni PL. „Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis“. *Arthritis Res Ther.* 2017 May 19;19(1):103.
36. Paroni M, Maltese V, De Simone M, Ranzani V, Larghi P, Fenoglio C, Pietroboni AM, De Riz MA, Crosti MC, Maglie S, Moro M, Caprioli F, Rossi R, Rossetti G, Galimberti D, Pagani M, Scarpini E, **Abrignani S**, Geginat J. „Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses“. *J Allergy Clin Immunol.* 2017 Sep;140(3):797-808.
37. Mazzara S, Rossi RL, Grifantini R, Donizetti S, **Abrignani S**, Bombaci M. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data“. *Sci Rep.* 2017 Mar 30;7:45477.
38. Ranzani V, Arrigoni A, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Next-Generation Sequencing Analysis of Long Noncoding RNAs in CD4+ T Cell Differentiation“. *Methods Mol Biol.* 2017;1514:173-185.
39. (**) Torri A, Carpi D, Bulgheroni E, Crosti MC, Moro M, Guarini P, Rossi RL, Rossetti G, Di Vizio D, Hoxha M, Bollati V, Gagliani C, Tacchetti C, Paroni M, Geginat J, Corti L, Venegoni L, Berti E, Pagani M, Matarese G, **Abrignani S**, de Candia P. „Extracellular microRNA signature of human helper T cell subsets in health and autoimmunity.“ *J Biol Chem.* 2017 Feb 17; 292(7): 2903-2915.

40. Fedeli M, Riba M, Garcia Manteiga JM, Tian L, Viganò V, Rossetti G, Pagani M, Xiao C, Liston A, Stupka E, Cittaro D, **Abrignani S**, Provero P, Dellabona P, Casorati G. „miR-17~92 family clusters control iNKT cell ontogenesis via modulation of TGF- β signaling“. Proc. Natl. Acad. Sci. U S A. 2016 Dec 20;113(51):E8286-E8295.
41. (**) De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C1, Bonnal RJP, Provasi E, Sarnicola M, Panzeri I, Moro M, Crosti M, Mazzara S, Vaira V, Bosari S, Palleschi A, Santambrogio L, Bovo G, Zucchini N, Totis M, Gianotti L, Cesana G, Perego R, Maroni N, Pisani Ceretti A, Opocher E, De Francesco R, Geginat J, Stunnenberg HG, **Abrignani S**, Pagani M. "Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells" Immunity. 2016 Nov 15;45(5):1135-1147
42. Stunnenberg HG; International Human Epigenome Consortium, Hirst M. "The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery" Cell. 2016 Nov 17;167(5):1145-1149.
43. Geginat J, Paroni M, Kastirr I, Larghi P, Pagani M, **Abrignani S**. „Reverse plasticity: TGF- β and IL-6 induce Th1-to-Th17-cell transdifferentiation in the gut“. Eur J Immunol. 2016 Oct;46(10):2306-2310.
44. Arrigoni A, Ranzani V, Rossetti G, Panzeri I, **Abrignani S**, Bonnal RJ, Pagani M. „Analysis RNA-seq and Noncoding RNA“ Methods Mol Biol. 2016;1480:125-35.
45. Paroni M, Magarotto A, Tartari S, Nizzoli G, Larghi P, Ercoli G, Gianelli U, Pagani M, Elli L, **Abrignani S**, Conte D, Geginat, Caprioli F. "Uncontrolled IL-17 Production by Intraepithelial Lymphocytes in a Case of non-IPEX Autoimmune Enteropathy." Clin Transl Gastroenterol. 2016 Jul 14;7(7):e182.
46. Nizzoli G, Larghi P, Paroni M, Crosti MC, Moro M, Neddermann P, Caprioli F, Pagani M, De Francesco R, **Abrignani S**, Geginat J. "IL-10 promotes homeostatic proliferation of human CD8+ memory T cells and, when produced by CD1c+ DCs, shapes naive CD8+ T-cell priming" Eur J Immunol. 2016 Jul;46(7):1622-32.

47. Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, Gagliani N, Meroni P, **Abrignani S**, Flavell RA. "The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer" *Cytokine Growth Factor Rev.* 2016 Aug;30:87-93.
48. (**) de Candia P, Torri A, Fedeli M, Viganò V, Carpi D, Gorletta T, Casorati G, Pagani M, Dellabona P, **Abrignani S**. "The circulating microRNome demonstrates distinct lymphocyte subset-dependent signatures". *Eur J Immunol.* 2016 Mar;46(3):725-31
49. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, Paroni M, Iseppon A, Moro M, Crosti MC, Stölzel K, Romagnani C, Moroni G, Ingegnoli F, Torretta S, Pignataro L, Annoni A, Russo F, Pagani M, **Abrignani S**, Meroni P, Flavell R, Geginat J. "IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus". *J Allergy Clin Immunol.* 2016 Jan;137(1):318-321.
50. Marabita F, de Candia P, Torri A, Tegnér J, **Abrignani S**, Rossi RL. "Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR." *Brief Bioinform.* 2016 Mar;17(2):204-12.

2015

51. Kastirr I, Crosti MC, Maglie S, Paroni M, Steckel B, Moro M, Pagani M, **Abrignani S**, Geginat J "Signal Strength and Metabolic Requirements Control Cytokine-Induced Th17 Differentiation of Uncommitted Human T Cells" *J Immunol.* 2015 Oct 15;195(8):3617-27.
52. Panzeri I, Rossetti G, **Abrignani S**, Pagani M "Long Intergenic Non-Coding RNAs: Novel Drivers of Human Lymphocyte Differentiation". *Front Immunol.* 2015 Apr 15;6:175.
53. Geginat J, Nizzoli G, Paroni M, Maglie S, Larghi P, Pascolo S, **Abrignani S**. "Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets". *Front Immunol.* 2015 Oct 13;6:527.

54. Sefer R, Reed SG, O'Hagan D, Malyala P, Doro U, Laera D, **Abrignani S**, Cerundolo V, Steinman L, Bertholet S. „Gaps in knowledge and prospects for research of adjuvanted vaccines“. *Vaccine*. 2015 Jun 8;33 Suppl 2:B40-3. doi: 10.1016/j.vaccine.2015.03.057.
55. Bonnal RJ, Ranzani V, Arrigoni A, Curti S, Panzeri I, Gruarin P, **Abrignani S**, Rossetti G, Pagani M. “De novo transcriptome profiling of highly purified human lymphocytes primary cells.” *Sci Data*. 2015 Sep 29;2:150051.
56. Cheroni C, Donnici L, Aghemo A, Balistreri F, Bianco A, Zanoni V, Pagani M, Soffredini R, D'Ambrosio R, Rumi MG, Colombo M, **Abrignani S**, Neddermann P, De Francesco R. “Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.” *PLoS One*. 2015 Sep 25;10(9):e0138546.
57. Mazzara S, Sinisi A, Cardaci A, Rossi RL, Muratori L, **Abrignani S**, Bombaci M. “Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis”. *PLoS One*. 2015 Sep 16;10(9):e0137927
58. Bonnal R JP, Rossi RL, Carpi D, Ranzani V, **Abrignani S**, Pagani M. “miRiadne: a web tool for consistent integration of miRNA nomenclature” *Nucleic Acids Res*. 2015 Jul 1;43(W1):W487-92.
59. (**) Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJP, Curti S, Provasi E, Sugliano E, De Francesco R, Geginat J, Bodega B, **Abrignani S**, Pagani M. “LincRNAs landscape in human lymphocytes highlights regulation of T cell differentiation by linc-MAF-4”. *Nat Immunol*. 2015 Mar;16(3):318-25.

2014

60. (**) Geginat J, Paroni M, Maglie S, Alfen JS, Kastir I, Gruarin P, DeSimone M, Pagani M, **Abrignani S**. “Plasticity of human CD4 T cell subsets”. *Front. Immunol*. 2014, 5:630.

61. (**) de Candia P, Torri A, Pagani M, **Abrignani S** "Serum microRNAs as biomarkers of human lymphocyte activation in health and disease" *Frontiers in Immunology*, 2013; 10:5-43.
62. Reghellin V, Donnici L, Fenu S, Berno V, Calabrese V, Pagani M, **Abrignani S**, Peri F, De Francesco R, Neddermann P. "NS5A inhibitors impair NS5A- PI4KIIIa complex formation and cause a decrease of PI4P and cholesterol levels in HCV-associated membranes." *Antimicrob Agents Chemother*. 2014 Dec;58(12):7128-40.
63. Kastirri I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, Crosti MC, Moro M, Steckel B, Steinfeld S, Stölzel K, Romagnani C, Botti F, Caprioli F, Pagani M, **Abrignani S**, Geginat J "IL-21 Is a Central Memory T Cell-Associated Cytokine That Inhibits the Generation of Pathogenic Th1/17 Effector Cells" *J Immunol*. 2014 Oct 1;193(7):3322-31.
64. (**) Dellabona P, **Abrignani S**, Casorati G "iNKT cell help to B cells: a cooperative job between innate and adaptive immune responses". *European Journal of Immunology*, 2014; 44(8):2230-7.
65. (**) Zingaretti C, De Francesco R, **Abrignani S**, "Why it is so difficult to develop an HCV preventive vaccine?". *Clinical Microbiology and Infection*, 2014 May; 20 Suppl. 5:103-9.
66. Colombatto P, Brunetto MR, Maina AM, Romagnoli V, Almasio P, Rumi MG, Ascione A, Pinzello G, Mondelli M, Muratori L, Rappuoli R, Rosa D, Houghton M, **Abrignani S**, Bonino F. "HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α 2a and Ribavirin: a randomized controlled trial". *J Viral Hepat*. 2014 Jul;21(7):458-65. doi: 10.1111/jvh.12163. Epub 2013 Aug 27.
67. Bottai D, Scesa G, Cigognini D, Adami R, Nicora E, **Abrignani S**, Di Giulio AM, Gorio A. "Third trimester NG2-positive amniotic fluid cells are effective in improving repair in spinal cord injury". *Exp Neurol*. 2014 Apr;254:121-33. doi: 10.1016/j.expneurol.2014.01.015. Epub 2014 Jan 29.

2013

68. (**) de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, Marabita F, Crosti M, Moro M, Pariani E, Romanò L, Esposito S, Mosca F, Rossetti G, Rossi RL, Geginat J, Casorati G, Dellabona P, Pagani M, **Abrignani S**, "Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation". *PLoS One*. 2013 Sep 26;8(9).
69. (**) Geginat J, Paroni M, Facciotti F, Gruarin P, Kastirr I, Caprioli F, Pagani M, **Abrignani S**, "The CD4-centered universe of human T cell subsets". *Semin Immunol*. 2013; 25(4):252-62.
70. Nizzoli G, Krietsch J, Weick A, Steinfeld S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M, Romagnani C, Stoelzel K, Torretta S, Pignataro L, Scheibenbogen C, Neddermann P, De Francesco R, **Abrignani S**, Geginat J., "Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses". *Blood*, 2013; 122(6): 932-42.
71. (**) Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, Geginat J, **Abrignani S**. "Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation". *Immunol Rev*. 2013; 253(1):82-96.
72. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, **Abrignani S**, Tyrrell DL, Houghton M., "A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans". *PLoS One* 2013; 8(3):e59776.
73. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, **Abrignani S**, De Francesco R, Colombo M. "IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B". *Hepatology* 2012; 57(3):890-6.
74. Delang L, Neyts J, Vliegen I, **Abrignani S**, Neddermann P, De Francesco R., "Hepatitis C virus-specific directly acting antiviral drugs". *Curr Top Microbiol . Immunol*. 2013; 369:289-320.

75. Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, **Abrignani S**, Reali E., "Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy". *Inflamm Bowel Dis*. 2013; 19(4):729-739.

2012

76. (**) Zingaretti C, Arigo' M, Cardaci A, Moro M, Crosti M, Sinisi A, Sugliano E, Cheroni C, Marabita F, Nogarotto R, Bonnal RJ, Marcatili P, Marconi M, Zignego A, Muratori P, Invernizzi P, Colombatto P, Brunetto M, Bonino F, De Francesco R, Geginat J, Pagani M, Muratori L, **Abrignani S**, Bombaci M, "Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis". *Mol Cell Proteomics*. 2012; 11(12):1885-97.
77. (**) Moro M, Crosti M, Creo P, Gallina P, Curti S, Sugliano E, Scavelli R, Cattaneo D, Canidio E, Marconi M, Rebullia P, Sarmientos P, Viale G, Pagani M, **Abrignani S**. "Identification of new hematopoietic cell subsets with a polyclonal antibody library specific for neglected proteins". *PLoS One* 2012; 7(4):e34395.
78. Novellino L, Rossi RL, Bonino F, Cavallone D, **Abrignani S**, Pagani M, Brunetto MR. "Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs". *PLoS One* 2012; 7(3), e31952.
79. Bottai D, Cigognini D, Nicora E, Moro M, Grimoldi MG, Adami R, **Abrignani S**, Marconi AM, Di Giulio AM, Gorio A. "Third trimester amniotic fluid cells with the capacity to develop neural phenotypes and with heterogeneity among sub-populations". *Restor Neurol Neurosci*. 2012;30(1):55-68.
80. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, **Abrignani S**, Neddermann P, De Francesco R. "Metabolism of Phosphatidylinositol 4-Kinase III α -Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity". *PLoS Pathog* 2012; 8(3):e1002576.

81. Tonti E, Fedeli M, Napolitano A, Iannacone M, Von Andrian UH, Guidotti LG, **Abrignani S**, Casorati G, Dellabona P. "Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help" *J. Immunol.* 2012; 188(7):3217-22.

2011

82. Stamataki Z, Coates S, **Abrignani S**, Houghton M, McKeating JA. "Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains". *J Infect Dis.* 2011; 204(5):811-3.
83. Grifantini R, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, Pileri P, Cattaneo D, Canidio E, Pontillo A, De Camilli E, Bresciani A, Marinoni F, Pedrazzoli E, Nogarotto R, **Abrignani S**, Viale G, Sarmientos P, Grandi G. "A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins" *J. Proteomics* 2011; 75(2): 532-47.
84. (**) Rossi RL., Rossetti G., Wenandy L., Curti S., Ripamonti A., Bonnal RJP., Sciarretta BR., Moro M., Crosti MC., Gruarin P., Maglie S., Marabita F., Mascheroni D., Parente V., Comelli M., Trabucchi E., De Francesco R., Geginat J., **Abrignani S**, Pagani M. "Distinct microRNA signatures in human lymphocyte subsets and enforcement of T cell naïve state by miR-125b". *Nature Immunol.* 2011; 12, 796-803.
85. Marabita, F., Aghemo, A., De Nicola, S., Rumi, M. G., Cheroni, C., Scavelli, R., Crimi, M., Soffredini, R., **Abrignani, S.**, De Francesco, R., and Colombo, M. "Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection". *Hepatology* 2011. 54(4), 1127-1134.
86. Bosè F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, Caprioli F, Scavelli R, Altomare G, Geginat J, **Abrignani S**, Reali E. "Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues ". *Clin Immunol.* 2011; 139(2):164-76.

2010

87. L. Rivino, P. Guarini, B. Häringer, S. Steinfelder, L. Lozza, E. Sugliano, A. Weick, D. Jarrossay, A. Kuehl, C. Loddenkemper, **S. Abrignani**, F. Sallusto, A. Lanzavecchia and J. Geginat "CCR6 is expressed on an IL-10 producing, auto-reactive memory T cell population with context-dependent regulatory function" *J. Exp. Med.* 2010; 207: 565-577.
88. Ray R, Meyer K, Banerjee A, Basu A, Coates S, **Abrignani S**, Houghton M, Frey SE, Belshe RB. "Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins". *J Infect Dis.* 2010; 202(6): 862-6.
89. Frey SE, Houghton M, Coates S, **Abrignani S**, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults". *Vaccine* 2010; 28(38): 6367-73.

2009

90. (**) **Abrignani S**, Tonti E, Casorati G, Dellabona P. "B cell helper assays". *Methods Mol Biol.* 2009; 514: 15-26.
91. Tonti E, Galli G, Malzone C, **Abrignani S**, Casorati G, Dellabona P. "NKT-cell help to B lymphocytes can occur independently of cognate interaction". *Blood* 2009; 113(2): 370-6.

2008

92. (**) Serra A, Nuti S, Tavarini S, Sammicheli C, Rosa D, Saletti G, Soldaini E, **Abrignani S**, Wack A. "Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function". *J Immunol.* 2008; 181(1): 174-85.

2007

93. Stamatakis Z, Coates S, Evans MJ, Waininger M, Crawford K, Dong C, Fong YL, Chien D, **Abrignani S**, Balfe P, Rice CM, McKeating JA, Houghton M. "Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies". *Vaccine*. 2007; 25(45): 7773-84.
94. (**) Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M, Maione D, Volpini G, Finco O, Nuti S, Tavarini S, Dellabona P, Rappuoli R, Casorati G & **S Abrignani**. "Invariant NKT cells sustain specific B cell responses and memory". *PNAS*. 2007; 104: 3984-9.

2006

95. Brazzoli M, Crotta S, Bianchi A, Bagnoli F, Monaghan P, Wileman T, **Abrignani S** & M Merola. "Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line". *J Hepatol*. 2006; 46: 53-59.
96. Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, **Abrignani S**, Lin YL, Houghton M & O'Hagan DT. "Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses". *J Gen Virol*. 2006; 87: 2253-2262.
97. Crotta S, Ronconi V, Olivieri C, Baldari CT, Valiente NM, **Abrignani S** & Wack A. "Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells". *Eur J Immunol*. 2006; 36: 919-929.

2005

98. (**) Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, Nuti S, Houghton M, Barnaba V, Pozzato G & **S Abrignani**. "Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte e disorders". *PNAS*. 2005; 102: 18544-18549.

99. Kong WP, Xu L, Stadler K, Ulmer JB, **Abrignani S**, Rappuoli R & GJ Nabel. "Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization". *J Virol.* 2005; 79: 13915-13923.
100. (**) Houghton M & **S Abrignani***. "Prospects for a vaccine against the hepatitis C virus". *Nature* 2005; 436: 961-966.
101. Capo S, Nuti S, Scarselli M, Tavarini S, Montigiani S, Mori E, Finco O, **Abrignani S**, Grandi G & G Bensi. "Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells". *Vaccine* 2005; 23: 5028-5037.
102. Mazzocca A, Cappadona Sciammetta S, Carloni V, Cosmi L, Annunziato F, Harada T, **Abrignani S** & M Pinzani. "Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells". *J. Biol. Chem.* 2005; 280: 11329-11339.
103. (**) Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, Ciccorossi P, Zorat F, Pozzato G, Comar C, **Abrignani S** & A Wack. "Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic Hepatitis C patients and healthy donors". *J. Hepatol.* 2005; 42: 61-67.
104. Brazzoli M, Helenius A, Fong SK, Houghton M, **Abrignani S** and M. Merola. "Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells". *Virology* 2005; 332: 438-453.

2004

105. (**) Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P & **Abrignani S**. "Association of hepatitis C virus envelope proteins with exosomes". *Eur. J. Immunol.* 2004; 34: 2834-2842.
106. Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, Uematsu Y, Harada T, Greer CE, Polo JM, Pileri P, Eickmann M, Rappuoli R, **Abrignani S**, Houghton M & JH Han. "Synthesis and characterization of a native, oligomeric form of

recombinant severe acute respiratory syndrome coronavirus spike glycoprotein". *J. Virol.* 2004; 78: 10328-10335.

107. De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, **Abbrignani S**, Casorati G & P Dellabona. "Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis". *J. Immunol.* 2004; 173: 1417-1425.
108. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, **Abbrignani S**, Mondelli MU & V Barnaba. "Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection". *J. Clin. Invest.* 2004; 113: 963-972.

2003

109. Stadler K, Massignani V, Eickmann M, Becker S, **Abbrignani S**, Klenk HD & R Rappuoli. "SARS--beginning to understand a new virus". *Nat. Rev. Microbiol.* 2003; 1: 209-218.
110. Eickmann M, Becker S, Klenk HD, Doerr HW, Stadler K, Censini S, Guidotti S, Massignani V, Scarselli M, Mora M, Donati C, Han JH, Song HC, **Abbrignani S**, Covacci A & R Rappuoli. "Phylogeny of the SARS coronavirus". *Science.* 2003; 302: 1504-1505.
111. (**) Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abbrignani**. "Innate immune responses support adaptive immunity: NKT cells induce B cell activation". *Vaccine.* 2003; 21: S2/ 48-54.
112. (**) Galli G, Nuti S, Tavarini S, Galli Stampino L, De Lalla C, Casorati G, Dellabona P & **S Abbrignani**. "CD1d-Restricted Help To B Cells By Human Invariant NKT Lymphocytes". *J. Exp. Med.* 2003; 197: 1051-1057.
113. (**) Soldaini E, Wack A, D'Oro U, Nuti S, Ulivieri C, Baldari CT & **S Abbrignani**. "T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck". *Eur. J. Immunol.* 2003; 33: 455-464.

114. Seo MY, **Abrignani S**, Houghton M & H Han. "Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7". *J. Virol.* 2003; 77: 810-812.

2002

115. Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, **Abrignani S** & Y Uematsu. "Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection". *Virology.* 2002; 304: 187-196.
116. (**) Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filipponi F, Brunetto RM, Bonino F, **Abrignani S** & N Valiante. "Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein". *J Exp Med.* 2002; 195: 35-41.

2001

117. Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, **Abrignani S**, Rappuoli R & G Grandi. "Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to *Haemophilus influenzae* type b oligosaccharide: a model for new conjugate vaccines". *Eur J Immunol.* 2001; 31: 3816-38240.
118. (**) Merola M, Brazzoli M, Cocchiarella F, Heile JM, Helenius A, Weiner AJ, Houghton M & **S Abrignani**. "Folding of hepatitis C virus E1 glycoprotein in a cell-free system". *J Virol.* 2001; 75: 11205-11217.
119. Burioni R, Bugli F, Mancini N, Rosa D, Di Campli C, Moroncini G, Manzin A, **Abrignani S**, Varaldo PE, Clementi M & G Fadda. "Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs". *Virology.* 2001; 288: 29-35, .

120. Agrati C, D'Offizi G, Narciso P, **Abrignani S**, Ippolito G, Colizzi V & F Poccia. "Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons". *Mol.Med.* 2001. 7: 11-19.
121. Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, **Abrignani S** & V Barnaba. "Virus-specific CD8⁺ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection". *Eur. J. Immunol.* 2001; 31: 894-906.
122. Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, **Abrignani S**, Grandi G & M Bolognesi. "CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs". *EMBO J.* 2001; 15: 12-18.
123. (**) Wack A, Soldaini E, Tseng CT, Nuti S, Klimpel GR & **S Abrignani**. "Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells". *Eur J Immunol.* 2001 ; 31:166-175.

2000

124. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, **Abrignani S** & SK Foug. "Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes". *J Virol.* 2000; 74: 10407-10416.
125. Allander T, Drakenberg K, Beyene A, Rosa D, **Abrignani S**, Houghton M, Widell A, Grillner L & MA Persson. "Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81". *J Gen Virol.* 2000 ; 81: 2451-2459.
126. (**) D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G & **S Abrignani**. "Neonatal invariant Valpha24⁺ NKT lymphocytes are activated memory cells". *Eur J Immunol.* 2000 ; 30: 1544-1550.
127. (**) Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Winger M, Baker G, Cousens L, Chien D, Ng P,

Archangel P, Grandi G, Houghton M & **S Abrignani**. "Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates". *J Virol*. 2000; 74: 6885-6892.

128. Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, **Abrignani S** & G Grandi. "Structure-function analysis of hepatitis C virus envelope-CD81 binding". *J. of Virol*. 2000; 74: 4824-4830.

129. (**) Valiante N, D'Andrea A, Crotta S, Lechner F, Klenerman O, Nuti S, Wack A & **S Abrignani**. "Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C". *Immunol. Rev*. 2000; 174: 77-89.

1999

130. (**) **Abrignani S**, Houghton M & HH Hsu "Perspectives for a vaccine against hepatitis C virus". *J Hepatol*. 1999, 31: 259-263.

131. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, **Abrignani S**, Sette A & V Barnaba. "Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors". *J Immunol*. 1999; 162: 6681-6689.

1998

132. (**) Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G & **S Abrignani**. "Binding of hepatitis C Virus to CD81". *Science*. 1998; 282: 938-941.

133. (**) Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V, & **S Abrignani**. "Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for V α 24+ T-cells and rapid elimination of effector cells by apoptosis". *Eur. J. Imm*. 1998; 28: 3456-3467.

134. (**) Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, **Abrignani S** & T Miyamura. "High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C". *Hepatology*. 1998; 28: 1117-1120.
135. Habersetzer F, Fournillier A, Dubuisson J, Rosa D, **Abrignani S**, Wychowski C, Nakano I, Trepo C, Desgranges C, Inchauspe G. "Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties". *Virology*. 1998; 249: 32-41.
136. Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, Bugli F, Solforosi L, **Abrignani S**, Varaldo PE, Fadda G & M Clementi. "Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments". *Hepatology*. 1998; 28: 810-814.
137. **Abrignani S**. "Antigen-independent activation of resting T-cells in the liver of patients with chronic hepatitis". *Dev. Biol. Stand.* 1998; 92: 191-194.
138. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kochen C, Thomas A, **Abrignani S** & G Grandi. "Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid". *Eur. J. Imm.* 1998; 28: 1225-1232.

1997

139. (**) **Abrignani S**. "Bystander activation by cytokines of intrahepatic T cells in chronic viral hepatitis". *Seminars in Liver Disease* 1997; 17: 319-322.
140. (**) **Abrignani S**. "Immune responses throughout HCV infection: HCV from the immune system point of view". Springer Seminars in *Immunopathology*. 1997; 19: 47-56.
141. (**) Finco O, Nuti S, Mangiavacchi L, Aiuti A, Forte P, Fantoni A, van der Putten H & **S Abrignani**. "Induction of CD4+ T-cell depletion in mice doubly transgenic for HIV-gp120 and human CD4". *Eur. J. Imm.* 1997; 27: 1319-1324.

1996

142. (**) Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner A, Lau J, Choo Q, Chien D, Pileri P, Houghton M & **S Abrignani**. "A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein-E2 binding to target cells". *PNAS* 1996; 93: 1759-1763.
143. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, **Abrignani S**, Douce G & M De Magistris. "Induction of antigen-specific antibodies in vaginal secretions using a non-toxic mutant of LT as a mucosal adjuvant". *Infect. Immun.* 1996; 64: 974-979.

1995

144. (**) Unutmaz D, Baldoni F & **S Abrignani**. "Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory cells". *Int. Immunol.* 1995; 9: 1417-1424.
145. **Abrignani S**. "Cellular immune reactions against hepatitis C core in chronic hepatitis C". *Gastroenterology* 1995; 108: 1957-1958.
146. Di Tommaso A, Xiang Z, Bugnoli M, Figura N, Bayeli P, Rappuoli R, **Abrignani S** & MT De Magistris. "Helicobacter Pylori specific CD4+ T cell clones from peripheral blood and gastric biopsies". *Infect. Immun.* 1995; 63:1102-1106.

1994

147. (**) Unutmaz D, Pileri P & **S Abrignani**. "Antigen-independent activation of naive and memory resting T cells by a cytokine combination". *J. Exp. Med.* 1994; 180: 1159-1164.
148. (**) Di Tommaso A, De Magistris MT, Bugnoli M, Marsili I, Rappuoli R & **S Abrignani**. "Formaldehyde-treatment of proteins can constrain presentation to T-cells by limiting antigen processing". *Infect. Immun.* 1994; 62: 1830-1834.

1993

149. (**) Minutello M, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Bonino F, Brunetto M & **S Abrignani**. "Compartmentalization of T-lymphocytes to the site of disease: Intrahepatic CD4⁺ T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis". *J. Exp. Med.* 1993; 178: 17-25.
150. (**) Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner AJ, Choo QL, Shuster J, Kuo G, Bonino F, Houghton M & **S Abrignani**. "T lymphocyte response to hepatitis C virus in different clinical courses of infection". *Gastroenterology* 1993; 104: 580-587.

1992

151. (**) Minutello M, Unutmaz D, Brunetto M, Kuo G, Bonino F, Houghton M & **S Abrignani**. "T-cell response to HCV in peripheral blood and liver and its correlation with protection and pathogenicity". *J. Hepatol.* 1992; 17, S1: 5-6.

1991

152. (**) Botarelli P, Houlden B A, Haigwood NL, Servis K, Montagna D & **S Abrignani**. "N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes". *J Immunol.* 1991 147(9):3128-32.

1990

153. (**) **Abrignani S**, Montagna D, Jeannet M, Wintsch J, Haigwood NL, Shuster JR, Steimer KS, Cruchaud A & T Staehelin. "Priming of CD4⁺ T cells specific for conserved regions of HIV-gp120 in humans immunized with a recombinant envelope protein". *Proc Natl Acad Sci USA.* 1990 87(16):6136-40.

1988

154. (**) Lanzavecchia A, Roosnek E, Gregory T, Berman P & **S Abrignani**. "T cells can present antigens such as HIV gp120 targeted to their own surface molecules". *Nature*. 1988 334(6182):530-2.
155. Lanzavecchia A, **Abrignani S**, Scheidegger D, Obrist R, Doerken B & G Moldenhauer. "Antibodies as antigen: the use of monoclonal antibodies to focus human T cells against selected targets". *J Exp Med*. 1988; 167(2):345-52.

Brevetti sottomessi e brevetti rilasciati

Titolo brevetto	Anno di priorità	N° domanda di brevetto	Nazione	Anno di Rilascio	N° di brevetto
Cancer treatment	2016	PCT/EP/2017/061642	Fase PCT		
Biomarkers for autoimmune liver diseases and uses thereof	2011	14125128	USA		
		2837522	CANADA		
		2012269083	AUSTRALIA	2016	2012269083
		127336154	EUROPA	2016	2721413
Prion chimeras and uses thereof	2003	2003279088	AUSTRALIA		
Eliciting HCV specific antibodies	1999	US12/001,920	USA		
Intracellular production of hepatitis C E1 and E2 truncated polypeptides	1997	10371040	USA	2008	US7429385 B2
Hepatitis C Receptor Protein Cd81	1997	EP1021534 A1	EUROPA		
		WO1999018198A1	USA	2006	US7097987 B2
Hepatitis C virus E2 binding protein	1995	11/372,935	USA	2008	US7320875 B2
T cell activation by cytokine combinations	1994	1995927917	EUROPA	2009	EP0772677 B1
		JP2006312640 A	JAPAN		
		2197801	CANADA		
		US2005/0281793 A1	USA		
Assay To Detect HCV Receptor Binding	1994	95927918.3	EU	2008	EP0723665 B2
		2174212 A	CANADA	2003	2174212 C
		DE1995632498	DENMARK	2004	69532498 D1
		1995/031894 A	AUSTRALIA		
		US11/784,521	USA		
		2004004113 A	JAPAN	2008	JP4117230 B2

Finanziamenti competitivi degli ultimi 10 anni

Titolo Progetto	Fonte del Finanziamento	Mia quota (EUR)	Periodo	Ruolo
"Innate and adaptive immunity in COVID-19: from mechanisms to patients"	Ministero della Salute	160.000	2020-2021	PI
"MalOMVax: a novel multi-stage and multi-antigen neutralizing vaccine against malaria infections"	Achilles Vaccines	1.500.000	2020-2021	PI
"Impatto dell'infezione di Covid-19 nelle malattie reumatiche croniche trattate con farmaci immunosoppressori (mainstream)"	Regione Lombardia	154.000	2020	PI
"Autoantibodies against specific human self-proteins as new diagnostic and prognostic biomarkers for Giant Cell Arteritis and Polymyalgia Rheumatica"	Ministero della Salute	90.000	2020-2023	PI
"HUNTER: Hepatocellular Carcinoma Expediter Network"	CRUK-AIRC	333.000	2018-2023	PI
"A Proposal To Develop Liquid Biopsies Based On The Identification Of Circulating Tumor-Derived Lymphocytes (Ctdl) To Choose And To Monitor Immunotherapy With Checkpoint Inhibitors"	Menarini	740.000	2017-2020	PI
"Insights into the evolving heterogeneity of metastatic colorectal cancer: from mechanisms to therapies"	AIRC 5x1000	2.335.000	2018-2025	PI
"Immunity in Cancer Spreading and Metastasis"	AIRC 5x1000	879.000	2018-2023	PI
Cluster Tecnologico Nazionale ALISEI: Progetto Medintech CTN01_00177_962865: "Cutting-edge technologies to increase safety and efficacy of drugs and vaccines"	Ministero dell'Istruzione e dell'Università e della Ricerca (MIUR)	994.500	2014-2017	PI
Grant n. 269022: i-MIRNOME - Lymphocyte microRNAs in health and disease: Understanding lymphocyte functions through the identification of microRNA target genes and exploiting serum microRNA signatures to monitor immune responses	ERC Advanced Grant	2.496.000	2011-2016	PI
Grant n. 2009-3603: "Improving vaccines for the developing world by means of new adjuvants potentiating effector and memory responses"	Fondazione Cariplo	489.919	2011-2014	Coordinatore
Grant n. RBAP10TPXK_002: "Eventi cellulari e molecolari nella patogenesi delle infezioni croniche da HBV o HCV"	Ministero dell'Istruzione e della Ricerca (MIUR)	343.300	2011-2016	PI
microRNA atlas in peripheral blood lymphocytes	Ministero della Salute e Regione Lombardia	2.000.000	2012-2013	PI
Hepacivac: LSH-2005-1.2.4-2 # 037435	Unione Europea - 6PQ	1.200.000	2005-2011	Coordinatore

|

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.
Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

SERGIO ABRIGNANI



Milano, 5 ottobre 2022